Neumora Therapeutics (NMRA) Profit After Tax (2022 - 2026)

Neumora Therapeutics' Profit After Tax history runs 5 years deep, the most recent figure standing at -$53.5 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 21.45% year-over-year to -$53.5 million in Q1 2026; TTM through Mar 2026 was -$222.4 million, a 13.79% increase from a year earlier, with the FY2025 full-year figure at -$237.0 million, up 2.73% from the prior year.
• Profit After Tax improved to -$53.5 million in Q1 2026 per NMRA's latest filing, from -$59.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$28.9 million in Q4 2022 and bottomed at -$109.2 million in Q4 2023.
• The 5-year median for Profit After Tax is -$53.7 million (2024), against an average of -$55.3 million.
• Across the five-year window, Profit After Tax tumbled 277.57% in 2023 and jumped 46.26% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$28.9 million in 2022, then tumbled by 277.57% to -$109.2 million in 2023, then soared by 46.26% to -$58.7 million in 2024, then slipped by 1.33% to -$59.5 million in 2025, then gained by 10.09% to -$53.5 million in 2026.
• Per Business Quant, the three latest NMRA Profit After Tax figures stand at -$53.5 million (Q1 2026), -$59.5 million (Q4 2025), and -$56.8 million (Q3 2025).